In Vitro Pharmacodynamics of Human Simulated Exposures of Telavancin against Methicillin-Susceptible and -Resistant Staphylococcus aureus with and without Prior Vancomycin Exposure
- 1 January 2016
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 60 (1) , 222-228
Abstract
Telavancin is a lipoglycopeptide with potent activity against methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-susceptible S. aureus (MSSA). The activity of telavancin against MRSA and MSSA after prior vancomycin exposure was studied in an in vitro pharmacodynamic model. Two clinical MRSA and two MSSA isolates, all with vancomycin MICs of 2 μg/ml, were subjected to humanized free drug exposures of vancomycin at 1 g every 12 h (q12h) for 96 h, telavancin at 750 mg q24h for 96 h, and vancomycin at 1 g q12h for 72 h followed by telavancin at 750 mg q24h for 48 h (120 h total). The microbiological responses were measured by changes from 0 h in log 10 CFU/ml at the end of experiments and area under the bacterial killing and regrowth curves over 96 h (AUBC 0−96 ). The control isolates grew to 8.8 ± 0.3 log 10 CFU/ml. Initially, all regimens caused −4.5 ± 0.9 reductions in log 10 CFU/ml by 48 h followed by slight regrowth over the following 48 to 72 h. After 96 h, vancomycin and telavancin achieved −3.7 ± 0.9 and −3.8 ± 0.8 log 10 CFU/ml changes from baseline, respectively ( P = 0.74). Sequential exposure to telavancin after vancomycin did not result in additional CFU reductions or increases, with ultimate log 10 CFU/ml reductions of −4.3 ± 1.1 at 96 h and −4.2 ± 1.3 at 120 h ( P > 0.05 for all comparisons at 96 h). The AUBC 0–96 was significantly smaller for the regimen of telavancin for 96 h than for the regimens of vancomycin for 96 h and vancomycin followed by telavancin ( P ≤ 0.04). No resistance was observed throughout the experiment. Against these MRSA and MSSA isolates with vancomycin MICs of 2 μg/ml, telavancin was comparable with vancomycin and its activity was unaffected by prior vancomycin exposure.Keywords
Funding Information
- Theravance Biopharma, Inc. (TLV-2014-024)
This publication has 34 references indexed in Scilit:
- Impact of patient characteristics and infection type on clinical outcomes of patients who received linezolid or vancomycin for complicated skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: a pooled data analysisDiagnostic Microbiology and Infectious Disease, 2014
- Are Vancomycin Trough Concentrations Adequate for Optimal Dosing?Antimicrobial Agents and Chemotherapy, 2014
- Vancomycin Tolerance in Methicillin-Resistant Staphylococcus aureus: Influence of Vancomycin, Daptomycin, and Telavancin on Differential Resistance Gene ExpressionAntimicrobial Agents and Chemotherapy, 2012
- Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA)International Journal of Antimicrobial Agents, 2011
- Successful treatment of methicillin-resistant Staphylococcus aureus endocarditis with telavancinJournal of Antimicrobial Chemotherapy, 2010
- Vancomycin-Associated Nephrotoxicity: Grave Concern or Death by Character Assassination?The American Journal of Medicine, 2010
- Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical proceduresThe American Journal of Surgery, 2009
- Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in BrazilClinical Microbiology and Infection, 2008
- Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureusJournal of Antimicrobial Chemotherapy, 2006
- Vancomycin Protein Binding in Patients with Infections Caused by Staphylococcus AureusDICP, 1991